gp100 (614-622)

gp100 (614-622) is a synthetic peptide fragment corresponding to amino acids 614 through 622 of the human glycoprotein 100 (gp100), a melanocyte differentiation antigen. As a well-characterized epitope, this peptide is frequently employed in immunological studies focused on antigen processing and T-cell recognition, particularly in the context of melanoma research. Its defined sequence and molecular specificity make it a valuable tool for dissecting the mechanisms of peptide-MHC binding, antigen presentation, and cellular immune responses. The availability of this peptide supports advanced studies in tumor immunology, epitope mapping, and the functional analysis of cytotoxic T lymphocyte (CTL) activity.

Epitope mapping: Researchers utilize gp100 (614-622) in the precise identification of T-cell epitopes recognized by cytotoxic lymphocytes. By incorporating this peptide into in vitro assays, scientists can systematically evaluate T-cell receptor specificity and map immunodominant regions within the gp100 protein. Such studies are critical for understanding immune surveillance mechanisms and for the rational design of immunotherapeutic strategies targeting melanoma-associated antigens.

Antigen presentation assays: The peptide serves as a model substrate for investigating the molecular dynamics of peptide loading onto major histocompatibility complex (MHC) class I molecules. Utilizing gp100 (614-622) in antigen-presenting cell (APC) cultures enables the assessment of peptide-MHC stability, presentation efficiency, and subsequent T-cell activation. These assays provide essential data for elucidating the cellular pathways governing antigen processing and for optimizing peptide-based vaccine platforms.

CTL functional studies: In functional immunological assays, gp100 (614-622) is widely used to stimulate antigen-specific CD8+ T cells, allowing for the evaluation of their cytolytic activity, cytokine release profiles, and proliferation. This application is instrumental in characterizing the effector functions of T cells directed against melanoma antigens, facilitating the development of adoptive cell transfer protocols and the assessment of immune response potency in preclinical models.

Peptide-MHC tetramer production: The defined sequence of gp100 (614-622) makes it an ideal candidate for the generation of peptide-MHC tetramers, which are powerful reagents for the detection and quantification of antigen-specific T-cell populations by flow cytometry. These tetramers enable high-resolution analysis of T-cell repertoire diversity, frequency, and functional status in both basic and translational immunology research.

Peptide library screening: As part of combinatorial peptide libraries, gp100 (614-622) can be employed in high-throughput screening approaches to identify cross-reactive T-cell receptors, study antigen mimicry, or explore immune escape variants. This application supports the discovery of novel immune targets and the investigation of antigenic determinants relevant to tumor immunology and immune modulation research.

By providing a reliable and well-characterized synthetic epitope, gp100 (614-622) facilitates a broad range of immunological investigations, advancing the understanding of antigen-specific T-cell responses and supporting innovative research in tumor immunology and peptide-based immunoengineering.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. Cationic cell-penetrating peptides are potent furin inhibitors

3. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury